Compare Bristol-Myers Squibb Co (BMY) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs LTC Properties Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $132.45B), while LTC Properties Inc trades at $38.12 (market cap $2.12B). The key difference: Bristol-Myers Squibb Co is far larger — about 62.5× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.78%). Which is the better fit depends on your goals.
| BMY | LTC | |
|---|---|---|
Market Cap | $132.45B | $2.12B |
Sector | Health | Real Estate |
52-Week High | $65.89 | $42.81 |
52-Week Low | $42.60 | $33.98 |
Enterprise Value | $166.44B | $2.86B |
Dividend Yield | 3.89% | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LTC Properties trades at $39.85, up 1.01% today, with a bullish technical signal supported by moving averages. The REIT shows strong fundamentals with a 14.08 P/E ratio, 38.93% net income margin, and consistent dividend payments of $0.19 monthly. Recent acquisitions in seniors housing (SHOP) portfolio total $285 million year-to-date, driving revenue growth from $210M in 2024 to $263M in 2025. However, earnings misses in two of the last three quarters and rising debt-to-asset ratio to 42.64% warrant caution.
Outlook remains positive due to demographic tailwinds in senior housing and aggressive SHOP expansion, but investors face risks from execution challenges in acquisitions and interest rate sensitivity. Analyst consensus is mixed with 27% buy ratings versus 59% hold, suggesting cautious optimism amid transition phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
